SV7 Impact Medicine
Venture capitalLondon · 4 people tracked
Find your way into SV7 Impact Medicine
Fund manager profile
SV7 Impact Medicine is a venture fund manager based in London. SEC filings show 1 venture fund on record, most recently SV7 Impact Medicine Fund LP ($250M offering) filed June 2019.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 4 people
from public directoriesWhat they invest in
from 1 of 1 portfolio companiesBiotech ×1Healthtech ×1
HQs:United States×1
Investments · 1 tracked
founders shown can be your intro path
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+8 more
Exits · 1
1 IPOsXilio TherapeuticsNASDAQ: XLO
Portfolio news
latest coverage across their companiesXilio Therapeutics · tickerreport.com · Aug 15, 2026
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SV7 Impact Medicine Fund, L.P.LPs: New Mexico Educational Retirement Board | 2019 | — | 16.2% | 1.50x | 0.62x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Xilio Therapeutics | 4.9% | $16.00 | Oct 2021 | $20.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- Where is SV7 Impact Medicine located?
- SV7 Impact Medicine is headquartered in London.